Nitto BioPharma is a biopharmaceutical company specializing in advanced nucleic acid drug delivery technologies. The company focuses on developing innovative drug delivery solutions, particularly through the use of novel biodegradable lipid nanoparticles (LNPs) that can target specific cells and efficiently deliver therapeutic agents. Their research has led to the creation of both lipid- and polymer-based platforms designed for the delivery of various genetic medicines, including siRNA, mRNA, and DNA. These delivery systems are engineered to ensure high levels of activity while maintaining safety and tolerability, making them suitable for clinical applications.

In addition to their drug delivery technologies, Nitto BioPharma emphasizes a collaborative approach to program development, aiming to bring pharmaceutical products to market efficiently. Their pipeline includes siRNA therapeutics targeting KRAS cancers and fibrotic diseases, which are currently in Phase 1 and Phase 2 clinical trials. The company also offers licensing opportunities for their proprietary Drug Delivery Solutions (DDS) platform, allowing partners to leverage Nitto's extensive research and development capabilities to enhance their own therapeutic pipelines. This commitment to innovation and partnership underscores Nitto BioPharma's mission to address unmet medical needs and improve patient outcomes.

United States

Nitto BioPharma is a clinical stage biopharmaceutical company located in San Diego focused on the discovery and development of novel RNA-based therapeutics for the treatment of fibrosis and other unmet medical needs. The company offers unique drug and siRNA delivery solutions by designing novel biodegradable delivery vehicles with the combined ability to target specific cells.

Nitto BioPharma

Company Details